Forte Biosciences, Inc. Announces Second Quarter 2020 Results and Provides General Business Update


TORRANCE, Calif.–(BUSINESS WIRE)–Forte Biosciences, Inc. ( (NASDAQ: FBRX), a clinical-stage biopharmaceutical company, today announced the second quarter 2020 financial results and provided a general business update.

“We are very happy to have concluded the reverse merger on June 15th and in that process, brought on a very well-respected group of investors, including Alger, BVF Partners, Franklin Templeton and OrbiMed to support Forte as we continue to grow the company. Our lead program, FB-401, developed in collaboration with the National Institute of Health (NIH) and the National Institute of Allergy and Infectious Diseases (NIAID), has shown

Celcuity Reports Second Quarter 2020 Financial Results and Recent Business Highlights


– Presented data for first CELsignia Pathway Activity Test for ovarian cancer at AACR Annual Meeting –

– Expect to announce new clinical trial collaborations with pharmaceutical companies and trial sponsors by the end of 2020 –

– Cash burn rate steady –

– Cash and Cash Equivalents of $15.4 million as of June 30, 2020, which is expected to support operations through 2021 –

– Conference Call on Monday, August 10th at 4:30pm (ET) –

MINNEAPOLIS, MN / ACCESSWIRE / August 10, 2020 / Celcuity Inc. (NASDAQ:CELC), a clinical stage biotechnology company translating discoveries of new cancer sub-types into

Mannatech Reports Second Quarter 2020 Financial Results


Mannatech, Incorporated (NASDAQ: MTEX), a global health and wellness company committed to transforming lives to make a better world, today announced financial results for its second quarter of 2020.

Second Quarter End Results

Second quarter net sales for 2020 were $37.6 million, a decrease of $3.1 million, or 7.5%, as compared to $40.7 million in the second quarter of 2019. Income from operations decreased to $1.1 million for the second quarter of 2020, from $2.0 million in the same period in 2019.

Net income was $1.1 million, or $0.47 per diluted share, for the second quarter of 2020, as compared

Biohaven Reports Second Quarter 2020 Financial Results And Recent Business Developments


– NURTEC™ ODT (rimegepant) achieved net revenues of $9.7M for the second quarter of 2020 and now NBRx market leader with 52.6% of share

– Company well-capitalized with recent non-dilutive financing of up to $950M from Sixth Street term loan and Royalty Pharma funding agreement

– Remains on timelines for NURTEC ODT sNDA filing for prevention of migraine in the coming months; additionally, completion of troriluzole Alzheimer’s Disease Phase 2/3 trial in 4Q2020, and topline results with troriluzole in Alzheimer’s Disease and Spinocerebellar Ataxia, and verdiperstat in Multiple System Atrophy in 2021

NEW HAVEN, Conn., Aug. 10, 2020 /PRNewswire/